Novel Genetic Switches Make Gene Therapies Safer and More Effective -Financieel Dagblad Interview (Nov 2024)
Article as featured in the Financieel Dagblad, 29 November 2024.
Annogen – KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops
A collaboration started in 2021 has led to the identification of sequence variants that upregulate important traits in plants, demonstrating the efficacy of SuRE™-based variant screening in crops.
Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters
Annogen announced a research collaboration with Orchard Therapeutics for the identification of immune cell-specific human promoters for pre-clinical hematopoietic stem cell gene therapy programs.
Annogen signs deal in which SuRE™ libraries are used for In-Vivo Capsid screening
Annogen will deliver its SuRE™ barcoding platform and downstream bioinformatics analysis to track tissue-specific biases for many AAV capsids in parallel.
Annogen introduces HEK293-INDX1™ – a clonal HEK293 cell line for inducible expression of toxic proteins such as Rep during AAV production
Annogen combined its SuRE™ promoter screening and AIM™ integration site screening platforms to establish HEK293 clones with near-zero baseline expression and high inducibility.
Annogen enters Contract Manufacturing market: AIM™ services and SuRE™ promoters
The AIM™ service, introduced in 2022 for cell therapy development, is now also available to the contract manufacturing market for virus and recombinant protein manufacturing.
Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE™ screening technology.
Annogen started a collaboration with another top agricultural science and technology company to test non-coding DNA fragments predicted to influence the expression of important crop traits.
VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters
VectorY Therapeutics and Annogen signed a Research Collaboration for the identification of CNS-cell specific synthetic promoters for VectorY’s vectorized antibody programs.
Annogen Announces Research Project with Pfizer to TestNon-coding Genetic Sequences
Annogen has begun a research project with Pfizer to functionally test tens of thousands of disease-related non-coding sequence variants for their effect on gene regulation.
Annogen introduces AIM™ service
A new service to identify gene insertions and assess their expression levels for >100,000 integrations in parallel.
